Table 4.

Associations of clinical characteristics with QTc ≥ 500 ms in combined SLE/RA cohort

Clinical covariates	Univariable model QTc ≥ 500 ms			Multivariable model QTc ≥ 500 msc
	OR	95% CI	p	OR	95% CI	p
Age	0.99	0.96–1.01	0.25	----------	----------	----------
Sex	1.12	0.49–2.57	0.79	----------	----------	----------
Race (white vs non-white)	0.92	0.48–1.76	0.79	----------	----------	----------
Disease duration (square root)	0.86	0.69–1.07	0.17	----------	----------	----------
Current HCQ use	0.21	0.11–0.44	< 0.01	0.39	0.16–0.98	0.044
Current prednisone use	0.43	0.23–0.81	0.010	0.55	0.23–1.34	0.19
Current biologic use	0.94	0.48–1.85	0.86	----------	----------	----------
Hypertension	1.37	0.74–2.55	0.31	----------	----------	----------
Current smoking	2.71	1.13–6.45	0.025	2.23	0.80–6.15	0.12
Diabetes	2.73	1.20–6.23	0.017	1.47	0.47–4.63	0.51
Current statin use	0.56	0.24–1.29	0.17	----------	----------	----------
Current aspirin use	0.39	0.18–0.83	0.015	0.60	0.23–1.56	0.29
Any QTc meds	1.14	0.63–2.07	0.66	----------	----------	----------
Antidepressants	2.41	0.88–6.56	0.085	1.30	0.52–3.23	0.58
Antipsychotics	1.14	0.13–9.83	0.90	----------	----------	----------
Antiarrhythmics	2.20	0.25–19.67	0.48	----------	----------	----------
Muscle relaxants	3.36	0.80–14.10	0.098	3.04	0.68–13.63	0.15
Antimicrobials	0.55	0.15–2.01	0.36	----------	----------	----------
Antiemetics	1.0	----------	----------	----------	----------	----------
Anticonvulsants	1.19	0.14–10.29	0.87	----------	----------	----------
Tacrolimus	4.29	0.90–20.33	0.067	4.31	1.06–17.53	0.042
Ejection fraction %	1.07	0.99–1.15	0.060	1.05	0.96–1.14	0.31
Ejection fraction ≥ 55%	1.79	0.42–7.63	0.43	----------	----------	----------
Prob > F	----------			0.0066

Abbreviations: HCQ hydroxychloroquine, QTcMeds QTc prolonging medications

^cFinal imputed data